L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Wake Forest Cancer Center CCOP Research Base
ClinicalTrials.gov Identifier:
NCT01105130
First received: April 14, 2010
Last updated: December 16, 2013
Last verified: December 2013
  Purpose

RATIONALE: L-arginine supplements may improve the quality of life and erectile function in men who are prostate cancer survivors.

PURPOSE: This randomized phase II trial is studying how well L-arginine supplementation works with or without enzyme inhibitors in treating erectile function and quality of life of prostate cancer survivors previously treated with radiation therapy.


Condition Intervention Phase
Male Erectile Disorder
Prostate Cancer
Radiation Toxicity
Drug: Placebo
Dietary Supplement: Oral L-arginine
Dietary Supplement: L-Arginine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Randomized Phase II Dose Finding Study of ArginMax for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated With Radiotherapy

Resource links provided by NLM:


Further study details as provided by Wake Forest Cancer Center CCOP Research Base:

Primary Outcome Measures:
  • Determine the best dose of ArginMax [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    The best dose will be defined as the one that results in the greatest improvement in erectile function.


Secondary Outcome Measures:
  • Assessment of Toxicity [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
  • Accrual for use in design of a subsequent Phase III clinical trial [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Retention for use in the design of a subsequent Phase III trial [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Adherence for use in the design of a subsequent Phase III clinical trial [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Quality of life and sexual function for use in the design of a subsequent Phase III clinical trial [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 140
Study Start Date: October 2010
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Arm I
Patients receive oral placebo twice daily (total of 6 capsules per day).
Dietary Supplement: Oral L-arginine
Given orally 3 capsules ArginMax and 3 Placebo capsules
Other Names:
  • ArginMax
  • Placebo
Experimental: Arm II
Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
Drug: Placebo
Given orally
Other Name: Placebo
Dietary Supplement: Oral L-arginine
Given orally 3 capsules ArginMax and 3 Placebo capsules
Other Names:
  • ArginMax
  • Placebo
Experimental: Arm III
Oral L-arginine twice daily = 6 capsules per day.
Dietary Supplement: L-Arginine
Patients will take 6 capsules of ArginMax twice daily
Other Name: ArginMax

Detailed Description:

OBJECTIVES:

Primary

  • To determine the "best dose" (defined as the dose that shows the greatest improvement in the erectile function domain of the International Index of Erectile Function [IIEF] after 8 weeks of therapy) of an L-arginine/Korean ginseng/gingko biloba/damiana-based supplement (L-arginine) to be used in a subsequent phase III trial in prostate cancer survivors previously treated with radiotherapy.

Secondary

  • Evaluate the toxicity of treatment with L-arginine with or without phosphodiesterase-5 inhibitors.
  • Estimate trial accrual, retention, adherence, and variability.
  • Assess changes in quality of life (QOL) and sexual function as defined by changes in the QOL of these patients using the Expanded Prostate Cancer Index Composite, changes in the other domains of the IIEF (i.e., orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction), changes in the Sexual Encounter Profile, and changes in the percentage of "yes" (positive) responses to either of the two global efficacy questions.

OUTLINE: Patients are stratified according to age (< 65 years vs ≥ 65 years) and current use of phosphodiesterase-5 (PDE-5) inhibitors (yes vs no). Patients are randomized to 1 of 3 treatment arms.

  • Arm I: Patients receive oral placebo twice daily (total of 6 capsules per day).
  • Arm II: Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
  • Arm III: Patients receive oral L-arginine twice daily (total of 6 capsules per day).

In all arms, treatment continues for 8 weeks in the absence of unacceptable toxicity.

Patients may also receive oral sildenafil, tadalafil, or vardenafil (PDE-5 inhibitors).

Patients complete the International Index of Erectile Function and the Expanded Prostate Cancer Index Composite-26 at baseline and at weeks 4 and 8. Patients also complete the Sexual Encounter Profile Questionnaire, FACT-P, and the Global Efficacy Questionnaire at weeks 4 and 8.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  • Male prostate cancer survivor previously treated with radiotherapy and who identifies himself as concerned with sexual quality of life, including erectile dysfunction. (seed implants are eligible)
  • Had successful sexual activity prior to the commencement of radiotherapy.
  • Erectile dysfunction, defined as inability to achieve or maintain an erection sufficient for satisfactory sexual performance
  • Interested in sexual activity and agrees to make at least one sexual intercourse attempt with a partner every week during the study.
  • The usage of PDE-5 inhibitors will be voluntary and will serve as a stratification factor. Patients taking PDE-5 inhibitors must agree to assume the responsibility for the cost of PDE-5 inhibitor treatment during the protocol period (8 week period) as this is not covered in the cost of the trial.
  • Patients currently taking PDE-5 inhibitors sildenafil (Viagra®, Pfizer Pharmaceuticals), tadalafil(Cialis®, Lilly ICOS, LLC), and vardenafil (Levitra®, Bayer Healthcare / Schering Plough Corp.)must agree to take the medication only as prescribed by their treating physician.
  • Patients taking PDE-5 inhibitors as part of this study must be on a stable dose of drug for at least one month prior to study entry.
  • Must be able to take oral medications.
  • > 6 months following completion of all cancer therapy
  • No evidence of prostate cancer
  • Prior malignancies allowed if no evidence of recurrent disease.
  • If previously taken LHRH agonist androgen suppression (e.g, Lupron, Zoladex), anti-androgen (e.g., Casodex, Eulexin, Nilandron), or estrogenic (e.g., diethylstilbestrol) agents, serum testosterone must have returned to the laboratory normal range
  • No planned surgery while on protocol or for 4 weeks following completion of protocol
  • Prior cystoscopy is permitted.
  • Age > 18
  • ECOG performance status 0/1.
  • Patients must agree not to start taking an herbal product for erectile dysfunction during the eight weeks of study intervention.

EXCLUSION CRITERIA:

  • No other concurrent erectile dysfunction therapies permitted (i.e. vacuum pump,cavernosal injections, and other drug therapies). Past use of these and other therapies permitted if the patient can meet the inclusion criteria above.
  • No testosterone supplementation permitted.
  • Use of LHRH agonist androgen suppression (e.g, Lupron, Zoladex), anti- androgen (e.g., Casodex,Eulexin, Nilandron), or estrogenic (e.g., diethylstilbestrol) agents within the last 6 months.
  • Prior prostate or lower genitourinary surgery (bladder, penis, urethra, testicles)including transurethral resection of prostate (TURP). (Prior vasectomy is allowed)
  • Serious cardiovascular disease (unstable angina, supraventricular arrhythmia, myocardial infarction, symptomatic congestive heart failure, cardiac arrhythmia, coronary artery bypass surgery within 6 months prior to registration).
  • Hypotension (<90/50mm Hg), or uncontrolled hypertension (>170/100 mm Hg)
  • Stroke or spinal cord injury within 6 months before registration.
  • Patients on Persantine, heparin, Lovenox, warfarin, ginkgo biloba, Plavix, Disalcid, other blood-thinning medication or with a history of bleeding disorders will be excluded.(Aspirin < 325mg allowed)
  • Current use of cimetidine, ketoconazole, itraconazole, erythromycin, or ritonavir. Major medical or psychiatric illness which, in the opinion of the investigator, would prevent completion of treatment or would interfere with follow-up.
  • Current or prior use of any organic nitrate within the last 6 months (e.g., use of nitroglycerin)
  • May not receive other investigational agents or devices during 30 days prior to start of study drug.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ArginMax (l-arginine, ginseng, or ginkgo biloba)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01105130

Locations
United States, North Carolina
W F Baptist Health
Winston Salem, North Carolina, United States, 27157
Sponsors and Collaborators
Wake Forest Cancer Center CCOP Research Base
Investigators
Study Chair: James J. Urbanic, MD Comprehensive Cancer Center of Wake Forest University
  More Information

Additional Information:
No publications provided

Responsible Party: Wake Forest Cancer Center CCOP Research Base
ClinicalTrials.gov Identifier: NCT01105130     History of Changes
Other Study ID Numbers: CCCWFU 98110, U10CA081851
Study First Received: April 14, 2010
Last Updated: December 16, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Wake Forest Cancer Center CCOP Research Base:
radiation toxicity
male erectile disorder
prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Radiation Injuries
Erectile Dysfunction
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Wounds and Injuries
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Sexual and Gender Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 16, 2014